Axsome Therapeutics Initiates FOCUS-2 Phase 3 Trial of Solriamfetol in Children with Attention Deficit Hyperactivity Disorder (ADHD)

The FOCUS-2 trial in children complements the recently announced FOCUS-3 trial in adolescents with ADHDNEW YORK, July 07, 2026 (GLOBE NEWSWIRE) ...
WV News

Notes from Nicki: Sometimes the strongest thing we can do is let go

I have never been one to sit back and just let things unfold. If there was a problem, I wanted to solve it. If there was a ...